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Dundee: J. Swanson Beck, P. Preece, M. Barclay, J. Horobin; Avon: P. Bradfield; Stoke: J. Scoble, N. Adams, J. Veitch;
Oxford: M. Vessey, E. Bale, A. Gatherer, M. Greenall.
Summary The limitations of case review as a means of identifying errors in death certificates among breast
cancer patients in a non-randomised trial of screening are illustrated by the findings of this large study.
Records of 928 out of 990 deaths were available for review but were very variable in quality. Definite errors
were found in 1%, errors were suspected in a further 5% and uncertainty about the cause of death, despite
review, was recorded for 27%. The overall bias in reporting breast cancer deaths was less than 1%. It was
concluded that the certified underlying cause of death without review provides an adequate endpoint for
evaluating breast cancer screening programmes in the UK.
Many breast screening services are now attempting to
evaluate their performance and will be faced with problems
concerning death certificate and cancer registry reliability
similar to those encountered in the Trial of Early Detection
of Breast Cancer (TEDBC). The most sensitive outcome
measure for assessing the success of intervention in the Trial
of Early Detection of Breast Cancer (UK Trial of Early
Detection of Breast Cancer Group, 1988) was deemed to be
death from breast cancer in patients who had first been
diagnosed with breast cancer after trial entry. First results
from the Trial (UK Trial of Early Detection of Breast
Cancer Group, 1988) relied on the underlying cause of death
stated on the death certificate but, because of the large body
of literature suggesting inaccuracy in death certificates (Git-
telsohn & Royston, 1982; Alderson & Meade, 1983; Cameron
& McGoogan, 1981) a system for reassessing the cause of
death was instituted. As the underlying cause of death is
always somewhat conjectural, whereas the presence of breast
cancer at death may be objectively demonstrated, the asses-
sors were additionally asked to state whether breast cancer
was present at death. This paper presents the findings of the
assessors regarding the reliability of the death certificate and
discusses the value of review.
Method of review
The TEDBC involves eight separate districts: Edinburgh and
Guildford which provided screening, Huddersfield and Not-
tingham which provided education in breast self-examination
(BSE) and four comparison districts, Oxford, Bristol, South-
mead, Dundee and Stoke which offered no special interven-
tion services. Details ofmethod (UK Trial of Early Detection
of Breast Cancer Group, 1981) and first results on mortality
(UK Trial of Early Detection of Breast Cancer Group, 1988)
are described elsewhere. The records of 99% of the women
were successfully flagged at the NHS Central Registries and
it is these women, aged 45 to 72, whose mortality has been
analysed. For flagged women who die the Scottish General
Registry Office (GRO) and National Health Service Central
Register for England and Wales (NHSCR) send the TEDBC
coordinating centre death certificates, with ICD-coded under-
lying causes of death, and also send cancer registration
notifications. Local research staff in the eight districts were
asked to find case notes for review on all cases where breast
cancer was mentioned on the death certificate unless cancer
was diagnosed before the woman's entry to the Trial, and on
all deaths of women who had had breast cancer diagnosed
since trial entry irrespective of the certified cause. They were
also informed ofdeaths from an unknown primary neoplasm
but, since funding was limited, the extent to which these
could be checked to ensure that a diagnosed breast cancer
had not been overlooked was variable. If a date ofdiagnosis
before trial entry was subsequently discovered the case was
excluded. Where no date could be found the date of death
was assumed to be the date of diagnosis.
Hospital case notes and/or radiotherapy records were the
main source of information, supplemented by autopsy
records, if available, and by records from GPs or private
hospitals and hospices, if the patient died other than in an
NHS hospital.
The records were reviewed by a designated local doctor (a
surgeon, radiotherapist or physician with a special interest in
breast cancer) and then either the entire case notes or
photocopied parts were also reviewed by the medically
qualified coordinating centre assessor(RE). The coordinating
centre staff sought and assessed records ofpatients who died
outside the Trial areas and also did so if local staffing
problems were holding up review. Thus only one assessor's
opinion was available for 8% of cases assessed.
The assessors were not blind to the source of the case. To
provide as full records as possible and yet disguise which
district they came from would have required greater
resources. A pilot study had found that differences between
assessors were due to overlooked or inadequate information
rather than to differences of opinion which might be resolved
by more expert scrutiny. The coordinating centre assessor
was therefore allowed to see the first assessor's opinion and
consulted with the first assessor if views confficted. Cases in
which the first assessor's opinion on the underlying cause of
death initially disagreed with the coordinating centre's
opinion amounted to 3.3% of the total reviewed by two
assessors. In some of these the first assessor agreed after
consultation, in others difference of opinion was due to the
arbitrariness of any conclusion based on inadequate evidence.
It is assumed that adoption of the coordinating centre's
opinion reduces inter-district bias in such cases. Opinions on
the cause of death were recorded either as definite or as
probable but uncertain.
Death was attributed to breast cancer if, in the opinion of
the assessor, the patient would not have died when she did,
had she not had a diagnosis of breast cancer. We did not
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specify the evidence required. Our definiton thus differs from
that used for the endpoint in the Swedish Two Counties
Study where published analyses (Tabar et al., 1985; Tabar et
al., 1989) are based on deaths in which breast cancer had
been histologically confirmed and where the persistence or
recurrence of the disease was also confirmed by one of a
number of specified investigations.
In this study, where the purpose is to assess the extent of
bias between districts as well as to identify definite mistakes,
probable errors as well as definite errors are reported.
The study is restricted to women who had been diagnosed
as having breast cancer after entry to the trial in 1979-1981
and follow-up covers the period to 31.12.87. False negative
errors among deaths certified as due to diseases other than
breast cancer (DOTBCs), and false positive errors among
deaths certified as due to breast cancer (DBCs), have been
estimated on the assumption that the assessors' verdict is
correct. Bias is defined as follows:
Bias = [(false positive - false-negative errors) x 100 + assessed DBCs]%
An overestimation bias implies that it is positive, an under-
estimating bias that it is negative, i.e. that false negative
errors exceed false positive errors.
Results
A total of 990 women were identified who had died before
1988 either with first mention of breast cancer on the death
certificate or with known diagnosis of breast cancer since
entry. For 17 (1.7%) of these no death certificate has been
received from NHSCR and a locally obtained death certificate
was used instead. As well as notifying the coordinating centre
about deaths, NHSCR had also sent a breast cancer registra-
tion for 832 (84%), which provided information on the date
of diagnosis. The date of diagnosis was known through
notification by local trial staff for a further 145 (14.6%)
whilst the date of death was assumed to be the date of
diagnosis for the remaining 14 cases (1.4%). The diagnosis of
breast cancer was considered on review to have been false or
insufficiently substantiated in six cases. For the purpose of
this review these six cases with mention of breast cancer on
the death certificate even though no breast primary had been
found are included.
Records were found for 928 (94%) of the 990 cases. Over
half of the 62 unreviewed cases resulted from staffing
difficulties in a single centre. The others could not be found
because records had been destroyed, sometimes as early as 3
years after death, or records were lost or stored inaccessibly.
Table I shows there was considerable variability between
districts in factors such as the proportion of deaths occurring
in hospital, which influence the type and reliability of records
available for review.
The co-ordinating centre assessor recorded that her verdict
on the underlying cause of death was probably correct but
uncertain in 250 (27%) and that there was uncertainty about
the presence of breast cancer at the time of death in 130
(14%).
The extent ofdisagreement
There was agreement between the assessors' opinion and the
death certificate on whether or not breast cancer was the
underlying cause of death in 94% (872/928) of all reviewed
cases (Table II). If, however, in those cases where the asses-
sors were uncertain because records were scanty, the certify-
ing doctors were given the benefit of the doubt, the number
of cases of disagreement between assessor and death
certificate would have been reduced from 56 (6.0%), as
shown in Table II, to 12 (1.3%). Table III shows the cir-
cumstances in which disagreements between death certificates
and review assessments occurred.
The certified underlying cause of death was breast cancer
in 84.8% and the review assessment agreed in 760/787
(96.6%) of these (Table II). Among those in which breast
cancer was not mentioned on the death certificate the assess-
ment agreed in 58/76 (88.2%). Where breast cancer was
mentioned but not coded as the underlying cause of death,
breast cancer was assessed to be the underlying cause in 20
(30.8%), to be present in a further 22 (33.8%) but absent and
non-contributory in 23 (35.4%), breast cancer having been
wrongly recorded in Part II of the certificate to signify that
the patient had once suffered from the disease.
Suspected false positive and false negative errors were
almost equal in number and hence resulted in very little
overall bias (i.e. less than 1%). If death with mention of
breast cancer on the death certificate were to be used as
end-point Table II shows that the number of errors would be
slightly greater, 58 (6.3%), and there would be a slightly
larger over-estimation bias, 2.7%, in comparison with the
assessors' verdict of whether breast cancer was present or
contributory.
Stage at diagnosis
Table IV shows, as expected that the probability of death
from breast cancer increased with advancing stage at diag-
nosis. The likelihood of finding false negative errors on the
Table I Variation between centres in factors which may affect reliability of death certificates and their review
Nott. Edin. Hudd. Guild Oxford Avon Stoke Dundee Total
Total
No. assessed
Breast cancer patients who died
within trial area
Breast cancerpatients who died
in own home
Breast cancerpatientswith autopsy
reported
With histo/cytological confirmation
ofbreast cancer
Stage IV atdiagnosis - as % ofbreast
cancerpatientdeaths
Breast cancerdeathswith additional
mention ofotherpathology on
certificate
Cancer registrations amongdeceased
breast cancerpatients
Percentageofalldeaths in the trial
population attributed to an
unknownprimary
170
170
89.4%
84
82
98.8%
40.6% 28.6%
17.6% 11.0%
86.1% 91.8%
23.0% 26.9%
17.0% 20.3%
93.5% (-)
3.3% 4.0%
87
80
93.5%
96
89
81.3%
133
95
91.0%
94
93
82.8%
227
224
97.8%
99
95
96.0%
990
928
91.9%
51.7% 19.8% 29.3% 35.1% 41.9% 19.2% 34.6%
6.9% 11.5% 5.3% 11.7% 17.2% 10.1% 13.4%
59.1% 77.9% 83.3% 95.6% 82.4% 83.8% 82.8%
33.3% 21.2% 18.0% 14.9% 22.4% 17.0% 22.0%
23.9% 20.2% 26.7% 25.3% 18.8% 31.7% 22.2%
85.1% 78.1% 72.9% 85.1% 83.3% (-) 83.5%
3.8% 3.5% 4.7% 3.5% 2.2% 3.9% 3.3%
(-)The system ofnotification ofregistrations forcases already known to trial staffwas different for the Scottish centres and
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Table II Status of breast cancer at death according to death certificate and to
assessors
BC on Death Certificate
As underlying As contributory Not Total
Assessors opinion cause cause mentioned reviewed
BC = Underlying cause 760 20 9 789
BC = Present but not 10 22 9 41
underlying cause
BC = Not present 17 23 58 98
Total reviewed 787 65 76 928
Not reviewed 53 5 4
Total eligible for review: 990.
Table III Situations leading to disagreement between certificate and
assessors
DC False DC False
Negatives Positive
1. Multiple causesofdeath mentioned
Caseswherecodingwould have been 5 (1)
altered byWHO Rule 3*
Otherinappropriate coding decisions 1 2(1)
2. Unknownprimarysuspected
Certifierapparently unaware ofbreast 3 (3)
cancer
Certifierguessed breast cancer but no 5
primary demonstrated in breast
3. Choicebetween twoprimaryneoplasms or 3 (1) 9(1)
possibility that one isasecondary
4. Sudden unexpecteddeath
Attributed tomyocardial infarction 6(1)
cerebrovascularaccident orperforated
pepticulcer, withoutsatisfactory
evidence, inpresence ofadvanced breast
cancer
Noevidence ofadvanced breast cancer 1
5. Chronic non-neoplastic disease
No evidence of metastatic breast cancer 8
(includes three with severe mental
disorder and another disease)
Moderate vascular disease with advanced 3(1)
breast cancer (includes one with severe
mental disorder)
6. Deathfollowing treatmentfor breastcancer 3 (1)
7. Autopsied
Prepost-mortem death certificate 3 (1) 2 (1)
Unsatisfactory PM report (histology 2
specimen lost, findingsinconsistent with
clinicaldata -clerical errorsuspected)
Total 29 (9) 27 (3)
) Numbers in brackets refer to definite errors.
*WHO Rule 3 recommends that breast cancer should be selected as
underlying cause of death even though only mentioned in Part II of
the certificate, in preference to certain specified conditions, e.g. bron-
chopneumonia.
death certificate also increased with stage (%2 for trend = 13.4,
p <0.001).
Age at death
The likelihood of dying from a cause other than breast
cancer rose with age, but age did not affect the likelihood of
finding false positive or false negative errors in the certified
cause of death (Table IV).
Length ofsurvival
Before 1988 few cases of death more than 5 years after
diagnosis had occurred. A further 45 cases dying later than
1987 which have also been reviewed have therefore been
included in Table IV. As expected, among those surviving
over 5 years, a larger proportion were certified to have died
of causes other than breast cancer and the death certificate
tended to be biased towards other causes.
Autopsy
Sixty-nine (8%) of the deaths attributed by the death
certificate to breast cancer, four (12%) of those attributed to
other cancers and 51 (67%) of those attributed to non-
neoplastic diseases had had an autopsy. There were no cases
in which breast cancer was first detected at autopsy. Death
certificate errors were suspected in 13 (10%) of those autop-
sied. In some this was because the death certificate had been
filled in before the post-mortem, and in some because in-
formation from the post-mortem report was transferred to
the death certificate without attempting to identify one
pathological condition as a dominant underlying cause of
death. The assessor was sometimes still left in doubt because
the histology report was missing or because the report did
not appear to account for the clinical history.
Differences between screening centres, BSE centres and
comparison districts
The proportion of breast cancer patients whose deaths were
from breast cancer, as predicted, was lowest (76.3%) in those
who had attended screening (Table V). Although there were
no significant differences in error rates between the different
types of centre an underestimation bias of - 2.2% in the
screening centres and an overestimation bias of 0.5% in the
BSE centres was observed. Three of the false negative errors
in Edinburgh, however, would have been more appropriately
coded as due to breast cancer if, as in England after 1983,
WHO Rule 3 had been adopted (OPCS, 1985). This rule
directs the coder to select breast cancer as underlying cause
of death even though mentioned only in Part II of the
certificate in preference to any of a number of specified
conditions, the commonest of which is bronchopneumonia (it
should be noted that in the report of the Edinburgh trial
using a randomised local control group (Roberts et al., 1990)
all cases in which breast cancer was mentioned on the death
certificate, including these, were included as breast cancer
deaths). Neither the difference in error rates between
attenders and non-attenders for screening or BSE education
nor between intervention centres and comparison centres are
statistically significant.
Using the assessors' verdict on whether breast cancer was
present or contributory to the cause of death, instead of the
standard end-point of deaths in which breast cancer was
certified as the underlying cause of death, increased 'breast
cancer deaths' by 19 (13.3%) in screening centres, 23 (10.3%)
in BSE centres and 37 (7.8%) in comparison centres. The
excess in the screening centres was in part due to the
occasional diagnosis of early stage breast cancer in women
with other, more advanced disease which made radical treat-
ment inappropriate.1154 J. CHAMBERLAIN et al.
Table IV Variation in concordance between death certificate and the review assessments of the cause of death
Breast cancer acc.
Total certificate (DBCs) False positives False negative Not
assessed No. (% of assd.) No. (% of DBCs) No. (% of DOTBCs) Bias assessed
All 928 787 (84.8%) 27 (3.4%) 29 (20.6%) - 0.3% 62
Stage
I & 1-S 109 73 (67.0%) 3 (4.1%) 2 (5.6%) + 1.4% 4
II 297 255 (85.9%) 7 (2.7%) 7 (16.7%) 0% 15
III & IV 476 424 (89.1%) 11 (2.6%) 20 (38.5%) - 2.1% 27
nk or n/a 46 35 (76.1%) 6 (17.1%) 0 (0%) + 17.1% 16
Pvalue <0.001 NS <0.001
(X2 for trend)
Age at death
<55 185 169 (91.4%) 7 (4.1%) 4 (31.3%) + 1.8% 15
55- 217 198 (91.2%) 4 (2.0%) 4 (21.1%) 0% 11
60- 273 226 (82.8%) 7 (3.1%) 13 (27.3%) - 2.7% 23
65- 253 193 (76.3%) 9 (4.7%) 8 (13.3%) + 0.7% 13
Pvalue <0.001 NS NS
(X2 for trend)
Length of survival*
<1 yr 293 249 (85.0%) 6 (2.4%) 12 (27.2%) -2.4% 20
1-4 535 464 (86.7%) 15 (3.2%) 10 (14.1%) + 1.1% 29
5 + 145 113 (77.9%) 2 (1.8%) 9 (28.1%) - 6.2% n/a
Pvalue NS NS NS
(X2 for trend)
Post mortem
Autopsy 124 69 (55.6%) 4 (5.8%) 9 (16.4%) - 7.2% 0
No autopsy 804 718 (89.3%) 23 (3.2%) 20 (23.3%) + 0.4% 62
Pvalue <0.001 NS NS
(x2, DF=1)
*Includes some deaths after 1987, excludes false diagnoses. NS - indicates Pvalue >0.1. False positive and false negative errors arejudged
in relation to the assessors' verdict. Bias = [(False positives - false negatives) x 100/DBCs]%. DOTBC = death certified as due to cause other
than breast cancer.
Table V Variation in concordance for different intervention groups
Breast cancer deaths
Total acc. certificate (DBCs) False positives False negative Not
assessed No. (% of assd.) No. (% of DBCs) No. (% of DOTBCs) Bias assessed
Screened centres
Attended screening 97 75 (76.3%) 2 (2.7%) 3 (13.0%) - 1.3% 5
Not screened 74 62 (83.8%) 2 (3.2%) 4 (33.3%) - 3.2% 4
Total 171 136 (79.5%) 4 (2.9%) 7 (20.0%) - 2.2% 9
NS NS NS
BSE centres
Attended education 101 91 (90.1%) 5 (5.5%) 4 (40.0%) + 1.1% I
Not educated 149 126 (84.6%) 3 (2.4%) 3 (13.0%) 0% 6
Total 250 217 (86.8%) 8 (3.7%) 7 (21.2%) + 0.5% 7
NS NS NS
Comparison centres
507 434 (85.6%) 15 (3.5%) 15 (20.5%) 0% 46
X2 test for differences between intervention centres and comparison centres yield P values > 0.05.
Discussion
The proportion of deaths with probable errors was 6% in
this study whereas Brinkley et al. (1984) in a study of 197
deaths of breast cancer patients in 1980 initially found they
disagreed with the death certificate in 9%. However, after
excluding cases where there was room for uncertainty, Brink-
ley et al., reported that ony six cases of error, all false
negative, three of them without mention of breast cancer on
the death certificate, were certain and concluded that the
death certificates gave a 4% underestimate of breast cancer
deaths among breast cancer patients who died up to 36 years
after diagnosis. Our error figures, when probable but uncer-
tain errors are ignored, is slightly lower, possibly because of
the adoption of WHO Rule 3 in 1984. Its adoption resulted
in an increase of 1% in deaths attributed to breast cancer in
England and Wales (OPCS, 1985). As the rule was not
adopted simultaneously in Scotland there is a slightly greater
underestimation bias in Edinburgh than in the English centres.
The low rate of detectable error in reporting death from
breast cancer in our study, confirms the findings of earlier
studies (Bauer & Robbins, 1972; Cameron & McGoogan,
1981; Waaler & Grimstead, 1958) which showed that cancers
are better recorded than other causes of death and that
breast cancer is among the best recorded cancers. The error
rate indicates that the certified cause of death provides an
adequate end-point for evaluating breast screening pro-
grammes in the United Kingdom at least up to 8 years from
entry. However the risk of errors may vary from place to
place: in Utrecht a check on breast cancer deaths found that
ten out of 56 were misclassified (Collette et al., 1984) due to
illegible writing. It is also possible that the chance of over-
looking breast cancer will increase in Britain as more women
are treated by methods which leave less visible evidence. The
visibility of the disease and of the scar left by treatment
probably explain why the accuracy of death certificates in
reporting breast cancer is so high (Engel et al., 1980).
Verification of the cause of death is now considered essen-CAUSE OF DEATH IN BREAST CANCER 1155
tial for all subjects in trials of cancer treatments (Hayward et
al., 1978) but is more difficult to organise in a population-
based cancer prevention or early detection trial because of
the large numbers involved. Most of the population die from
causes which it would be far-fetched to suggest are related to
intervention. Review is therefore selective. In the HIP study
review was carried out on 28% of all breast cancer patients
deaths, being limited to those cases in which disease other
than breast cancer was mentioned on the death certificate. In
the TEDBC this would have reduced the number of breast
cancer patient deaths needing review by 81% but would have
missed 16 (29.6%) of the errors.
A major benefit of review mentioned by Hayward et al.
(1978), namely that knowledge that it will take place
encourages better record keeping, was absent from this trial
as it was impractical to keep all clinicians caring for breast
cancer patients informed about the trial. Our study also may
be criticised for not conducting 'blind' review but we con-
sider that blinding would have added little to the reliability
of our findings and might have hampered perusal of all
relevant information. Bias due to inter-district variation in
the thoroughness of investigation, exemplified by the varia-
tion in rates of histological confirmation and rates of autopsy
shown in Table I, was of far greater concern. Increased
autopsy would undoubtedly improve reliability though the
error rate found in those actually autopsied exaggerates the
inaccuracy of clinical diagnosis due to the selection of
difficult cases for autopsy (Cameron & McGoogan, 1981).
Previous studies have commented on the greater inaccuracy
of death certificates of patients who die at home (Jablon et
al., 1966), patients with a short hospital admission (Alderson
& Meade, 1967), and patients dying in non-teaching hospitals
(Waldron & Vickerstaff, 1977).
In the Swedish Two Counties trial and in New York,
review was conducted by two or more independent assessors
who were blinded to the source of the case. Blinding in these
randomised trials was easier than in the UK trial because
cases and controls were usually treated in the same institu-
tions. However, even in the New York trial and the Two
Counties trial the validity of reviewers conclusions are not
immune from a bias which could favour screening. Both
studies (Shapiro et al., 1988; Tabar et al., 1989) state that the
stage at diagnosis of the breast cancer is taken into account
when assessing the likelihood that it was the cause of death.
Intervention is directed at changing the stage at diagnosis. It
may also alter the relationship between stage and prognosis
(Chamberlain, 1982). The purpose of making population-
based mortality comparisons rather than case-fatality com-
parisons is the avoidance of lead time bias and length-biased
sampling effects but, if stage is taken into consideration in
judging between competing causes of death, review of the
cause of death is unhelpful. Unfortunately there is no way to
avoid this problem completely. Even with meticulous autopsy
the origin of metastasis is judged on the basis of probability
rather than on unique features of breast neoplasm. The
number of cases with two cancers of different sites is, how-
ever, small (less than 6%, excluding skin cancers) in this
study.
Table VI shows the variation in end-points used in
different trials. In all of them analysis is restricted to cases
diagnosed after trial entry. In the Two Counties study, as in
the New York study, the assessed cause of death rather than
the official cause was used for the main mortality analyses
and differences between the two have not yet been published.
Only the Malmo study (Andersson et al., 1988) has so far
reported on the discrepancies produced by using reviewed
end-points in place of end-points based on official statistics.
One hundred and ninety-three deaths were reviewed there,
yielding 112 which were assessed to be due to breast cancer.
Disagreement with the death certificate was slightly greater
than in our study, 10% vs 6%, and this may be due to the
higher proportion of DOTBCs in the review or to the excep-
tionally high autopsy rate achieved, 63% compared with
17%. Heasman and Lipworth (1966) have shown that
autopsy tends to increase deaths attributed to breast cancer.
Is independent review ofthe cause ofdeath worthwhile?
This study has found that the underlying cause of death and
the presence of breast cancer at death often cannot be deter-
mined with certainty becuase of the inadequacy of available
evidence. Review allows correction of a small number of
errors but does not remove the possibility of biases depend-
ent on the thoroughness of investigation or, since false
negative errors will not be discovered if cases apparently
dying from other causes are not identified for review, on the
completeness of ascertainment of incident breast cancer
cases. Nor does it remove bias dependent on stage at diag-
nosis which is a serious deficiency where screening is under
evaluation. It introduces the risk of research hypothesis
affected bias and it reduces comparability with official stastis-
tics. It is however possible that death certificate errors may
increase with increasing duration of the interval since diag-
nosis and that this will warrant a further study of deaths in
long-term survivors.
We conclude that the certified underlying cause of death
currently provides the most appropriate major end-point for
evaluating screening programmes in England though possibly
in Scotland death with mention of breast cancer is more
appropriate. Assessment of the extent of bias by a method
which avoids case-review will be discussed in a separate paper.
Improvement in the monitoring and evaluation of screen-
ing in Britan will best be served by improving the cancer
registration system in order to ascertain all new cases and
their dates of diagnosis, rather than by organising independ-
ent review of case-notes of patients with breast cancer who
die.
We are indebted to many people working in the eight participating
centres and the trial co-ordinating centre for help in finding records.
We also wish to thank the staff of the NHS Central Registers and
the Family Practitioner Committees and the many consultants and
General Practitioners who have contributed information for this
study over the years. The work has been supported by the Depart-
ment of Health Research Management Division.
Table VI End-points used in reporting mortality results
Deathcertificate or
Study 'Breast cancerdeath'definition reviewassessment
HIPstudy Underlyingcause ofdeath Reviewed
Twocounties study Causeofdeath orpresentat death Reviewed
Malmo study Underlying cause ofdeath (a) Deathcertificate
(b) Reviewed
TEDBC Underlyingcauseofdeath Death certificate
Edinburgh RCT Underlying orcontributing cause ofdeath Death certificate1156 J. CHAMBERLAIN et al.
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